Contact
News
Stock Info
Governance
Financials & Filings
Resources

*

Stock

Stock info

icon

Upcoming Events

Nov 21, 2024 from 8:00 AM to 11:30 AM EST
GE HealthCare Investor Day

New York City
Presentations: 8:00 AM EST – 11:30 AM EST
Technology Showcase to follow presentations for in-person attendees

Add to Outlook
Add to Google Calendar
Webcast
Show all

GE HealthCare Third Quarter 2024 Earnings Conference Call

Webcast
Presentation 723.4 KB
Press Release 1 MB
Earnings Supplemental Info 99.8 KB

Sustainability Report

GE HealthCare’s 2023 Sustainability Report

Sustainability Report

View all events

>$1bn

annual R&D spend in 2023

1bn+

patients served annually

4m+

units installed across the globe

$19.6bn

revenue in 2023

News & events

Stay up to date with GE HealthCare's latest investor news and events

November 18, 2024

Pilot Study Showcases the Value of Portrait Mobile Continuous Monitoring Solution to Encourage Clinical Intervention While Mitigating Alarm Fatigue

News Release arrow-icon

November 13, 2024

GE HealthCare Receives FDA Clearance for Head-Only SIGNA MAGNUS 3.0T MRI System

News Release arrow-icon

November 12, 2024

GE HealthCare Announces Initiative to Help Address Radiologic Technologist Shortage

News Release arrow-icon

Nov 21, 2024 from 8:00 AM to 11:30 AM EST
GE HealthCare Investor Day
Add to Outlook
Add to Google Calendar
Webcast
October 30, 2024 at 8:30 AM EDT
GE HealthCare Third Quarter 2024 Earnings Conference Call
Listen to webcast
September 5, 2024 at 1:05 PM EDT
Morgan Stanley 22nd Annual Global Healthcare Conference
Webcast
More information is coming soon.

A message from the President & CEO of Pharmaceutical Diagnostics

Kevin ONeil
quote-icon

GE HealthCare is committed to innovating and investing to shape the future of molecular imaging, increasing diagnostic confidence and addressing unmet patient needs. We're particularly excited about Flyrcado, the first and only FDA-approved F18 PET myocardial perfusion imaging tracer for the detection of coronary artery disease, and we see significant advancements and opportunities to drive more personalized care in the space.”

Kevin O’Neill, President & CEO of Pharmaceutical Diagnostics, GE HealthCare

Quick Links

SEC Filings

FAQs

Contacts

Institutional and fixed income investors

Carolynne Borders, Investor relations

carolynne.borders@gehealthcare.com

Attn: Investor relations

GE HealthCare

500 West Monroe Street

Chicago, IL 60661

Retail investors

Erin Sekula, Investor relations

erin.sekula@gehealthcare.com

Attn: Investor relations

GE HealthCare

500 West Monroe Street

Chicago, IL 60661

Transfer agent

Equiniti Trust Company

www.shareowneronline.com

+1-833-914-2122 (toll free)

+1-651-450-4064 (international number)

GE HealthCare Investor Relations

investor@gehealthcare.com

833-735-1139

Stay connected with investor news

ge-icon

Investor Relations

GEHealthcare.com

© 2024 GE HealthCare

Cookies
Careers
Compliance
Privacy